Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-08-03 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
PXS Commences Final Cohort Dosing in Phase 1c Cancer Trial 3 pages 117.0KB
Regulatory Filings Classification · 95% confidence The document is a media release dated August 4, 2021, announcing clinical trial progress and results for Pharmaxis Ltd's drug candidate PXS-5505 in a phase 1c/2a trial for myelofibrosis. It contains no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. It is a corporate announcement about clinical trial progress and drug development status, not a financial report or regulatory filing. It is not a call transcript, board change, or capital update. The document is a press release providing operational updates on drug development and clinical trial progress, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-08-03 English
Investor Presentation Quarterly Shareholder Update 7 pages 1.0MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and dated 29 July 2021. It contains forward-looking statements, an executive summary, detailed updates on clinical trials, cash and capital structure, shareholder information, and anticipated news flow. The content is typical of a presentation aimed at investors, focusing on company strategy, financial position, and pipeline progress rather than detailed financial statements or regulatory disclosures. The length is 6286 characters, which is consistent with a presentation document rather than a full annual or interim report. There is no indication that this is an official regulatory filing, audit report, or earnings release. Therefore, the document best fits the category of an Investor Presentation (IP).
2021-07-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 5 pages 185.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly cash flow report for entities subject to Listing Rule 4.7B'. It contains detailed quarterly cash flow statements including operating, investing, and financing activities, with specific financial figures for the current quarter and year to date. The presence of detailed financial data for a quarter and the reference to a quarterly period (30 June 2021) indicates this is a comprehensive interim financial report rather than a brief announcement or certification. The document aligns with the definition of an Interim / Quarterly Report (IR), which includes substantive financial data and analysis for a period shorter than a full fiscal year. Q4 2021
2021-07-27 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – June 2021' and contains detailed information about the company's drug development programs, clinical trials progress, business restructuring, and outlook for the rest of the year. It includes substantive financial and operational data relevant to a quarter, such as milestone payments, clinical trial phases, and funding details. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content aligns with a comprehensive financial and operational report for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). There is no indication that this is an earnings release (which would be more summary and highlight-focused), nor is it an annual report or other category. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2021
2021-07-27 English
Pharmaxis Quarterly Shareholder Investor Briefing 2 pages 128.0KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 27 July 2021 from Pharmaxis Ltd announcing a Quarterly Shareholder Update and an investor briefing scheduled for 29 July 2021. It invites investors and analysts to participate in a virtual briefing consisting of a short presentation and Q&A session. The document does not contain actual financial statements or detailed financial analysis but rather announces the upcoming event and provides registration details. The document length is 4943 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this document contains the actual quarterly report or detailed financial data. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming investor event and report release, not the report itself.
2021-07-26 English
Pharmaxis Shareholder Investor Call - Corrected Link 2 pages 127.6KB
Investor Presentation Classification · 90% confidence The document is a media release dated 27 July 2021 from Pharmaxis Ltd announcing a Quarterly Shareholder Update and an investor briefing scheduled for 29 July 2021. It mentions the release of a quarterly update and an upcoming presentation with Q&A, but does not contain actual financial statements or detailed financial data itself. The document is short (4935 characters) and serves as an announcement for an event and report release rather than the report itself. Therefore, it fits the category of an Investor Presentation (IP) announcement or a Regulatory Filing (RNS). However, since it specifically invites investors to a briefing with a presentation and Q&A, it aligns best with the Investor Presentation (IP) category rather than a generic regulatory filing or report publication announcement. Hence, the classification is Investor Presentation (IP) with high confidence.
2021-07-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.